CORONA Remedies Limited (CORONA) reports Q1 FY27 revenue and PAT growth of 21.9% and 30.1% Y-o-Y, driven by brand building and operational excellence.
CORONA Remedies Limited commercialises India's most advanced EU-GMP approved women's hormone manufacturing facility, marking a significant milestone in women.
CORONA Remedies Limited (CORONA) secures EU-GMP accreditation for its Hormone and Oral Solid Dosage facilities, boosting its global market expansion.